Companies Dominating the Psychedelic Drugs Landscape
- Compass Pathways Plc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Mind Medicine Inc.
- Jazz Pharmaceuticals plc
- Johnson & Johnson Pte. Ltd.
- Hikma Pharmaceuticals PLC
- Thoughtful Brands Inc.
- Pfizer Inc.
- F. Hoffmann-La Roche AG
- Avadel Pharmaceuticals plc
- NRx Pharmaceuricals, Inc.
Browse Key Market Insights with Data Illustration:
In the News
- Compass Pathways Plc. a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that the American Medical Association (AMA) has approved a Current Procedural Terminology (CPT) III code for psychedelic therapies. The expected release of the full details of the code by the AMA is in July 2023 and the code will go into effect when it is published on January 1, 2024.
- Mind Medicine Inc., a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, announced that its collaborators at the University Hospital Basel (UHB) and the University Hospital of Psychiatry, have released positive topline data from an investigator-initiated trial (double-blinded) evaluating lysergide in the treatment of Major Depressive Disorder (MDD)
